Nierenzellkarzinom

Titel
Studie
Jahr

Everolimus as second-line therapy for metastatic renal cell carcinoma: final results of phase IV study MARC-2.

M. Staehler, D. Christoph, M. Stöckle, J. Harde, A. Stenzl, D. Klein, I. Benz-Rüd, V. Grünwald, 2018.

Oncol Res Treat 41 (suppl 4)(P610).

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

MARC-2
2018

Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PRO Kidney registry.

Kirste, T., Werner, T., Scheffler, M., Hamm, N., Eckert, R., Pelz, H., Fichter, C., Müller, L., Sahlmann, J., Potthoff, K., 2018.

Oncol Res Treat 41 (suppl 4)(P608).

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

PRO Kidney
2018

First-line pazopanib in poor-risk patients with metastatic renal cell carcinoma.

Staehler, M., Panic, A., Merling, M., Vannier, C., Hermann, E., Hogrefe, C., Potthoff, K., Grünwald, V., 2018.

Oncol Res Treat 41 (suppl 4)(P606).

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

FLIPPER
2018

Treatment reality and outcome data of patients with advanced papillary cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Goebell, P., Müller, L., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P339), 96.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2017

Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P.J., Müller, L., Staehler, M., Müller, Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(V420), 114.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2017

Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Goebell, 2017.

Oncol Res Treat 40 (suppl 3)(P343), 97–98.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

PAZOREAL
2017

Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Müller, L., Goebell, P. J., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(909P).

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TNK
2017

Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P. J., Müller, L., Staehler, M., Müller, M., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(902P). doi:10.1093/annonc/mdx365

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TNK
2017

Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-Pazopanib versus Pazopanib-Sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II).

Retz, M., Bedke, J., Herrmann, E., Grimm, M., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Frank, M., Gschwend, J., 2017.

Ann Oncol 28 (Supplement 5)(8450), v295–v329. doi:10.1093/annonc/mdx371

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

SWITCH II
2017

Interim Results from PAZOREAL: A Non-interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changine mRCC Treatment Landscape.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2017.

Ann Oncol 28 (Supplement 5)(899P), 318–319. doi:10.1093/annonc/mdx371

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

PAZOREAL
2017

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.

Goebell, P.J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Welslau, M., 2017.

Future Oncol 0(0). doi:10.2217/fon-2017-0083 (epup ahead of print)

Indikation: Nierenzellkarzinom; Veranstaltung: -; Journal: Future Oncology

PAZOREAL
2017

Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.

Marschner, N., Müller, L., Münch, A., Blumenstengel, K., Hutzschenreuter, U., Busies, S., 2017.

J Oncol Pharm Pract 23(4), 288–295. doi:10.1177/1078155216632379

Indikation: Nierenzellkarzinom; Veranstaltung: -; Journal: Journal Oncology Pharmacy Practice

TNK
2017

The PAZOREAL Non-Interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changing Metastatic Renal Cell Carcinoma Treatment Landscape.

Goebell, P., Doehn, C., Grüllich, C., Steiner, T., Ehneß, R., Welslau, M., 2016.

Ann Oncol 27(suppl_6), 852P. doi:10.1093/annonc/mdw373

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

PAZOREAL
2016

Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.

Marschner, N., Staehler, M., Müller, L., Nusch, A., Harde, J., Koska, M., Jänicke, M., Goebell, P.J., RCC Registry Group, 2016.

Clin Genitourin Cancer. Clin Genitourin Cancer 15(2), e209–e215. doi:10.1016/j.clgc.2016.08.022

Indikation: Nierenzellkarzinom; Veranstaltung: -; Journal: Clinical Genitourinary Cancer

TNK
2016

A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study.

Goebell, P.J., Müller, L., Hurtz, H.-J., Koska, M., Busies, S., Marschner, N., 2016.

Clin Genitourin Cancer, 63–68. doi:10.1016/j.clgc.2015.09.004

Indikation: Nierenzellkarzinom; Veranstaltung: -; Journal: Clinical Genitourinary Cancer

TNK
2016

The PAZOREAL study: A non-interventional study to assess efficacy and safety of Pazopanib and everolimus in a real life settin; reflecting a changing mRCC treatment landscape.

Goebell, P.-J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Welslau, M., 2016.

Oncol Res Treat 39 (suppl.3)(P883), 267. doi:10.1159/000449050

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

PAZOREAL
2016

Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry.

Marschner, N., Müller, L., Staehler, M., Nusch, A., Münz, M., Koska, M., Jänicke, M., Goebell, P., 2015.

Oncol Res Treat 38 (suppl.5)(V674), 204. doi:10.1159/000439070

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2015

Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry.

Goebell, P., Müller, L., Staehler, M., Nusch, A., Münz, M., Koska, M., Jänicke, M., Marschner, N., 2015.

Eur Urol Suppl 14 (2)(abstract 6), e6. doi:10.1016/S1569-9056(15)60009-4

Indikation: Nierenzellkarzinom; Veranstaltung: EAU; Journal: European Urology

TNK
2015

SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Michel, M.S., Vervenne, W., Santis, M. de, Weikersthal, L.F. von, Goebell, P.J., Lerchenmueller, C., Zimmermann, U., Bos, M.M.E.M., Freier, W., Schirrmacher-Memmel, S., Staehler, M.D., Pahernik, S., Los, M., Schenck, M., Flörcken, A., Arkel, C.V., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., 2014.

J Clin Oncol 32(suppl 4; abstr 393). doi: 10.1200/jco.2014.32.4_suppl.393

Indikation: Nierenzellkarzinom; Veranstaltung: GCS (ASCO); Journal: Journal of Clinical Oncology

RCC-SWITCH
2014

Prediction of second-line therapy response by plasma proteins in patients with metastatic renal cell carcinoma.

Hölters, S., Ohlmann, C., Bergmann, L., Grünwald, V., Keilholz, U., Staehler, M., Fecher-Trost, C., Schalkowsky, P., Schmerler, D., Junker, K., 2015.

Indikation: Nierenzellkarzinom; Veranstaltung: SWDGU; Journal: -

MARC-2
2014

Plasma proteins characterize second-line therapy response in progressive renal cell carcinoma.

Hölters, S., Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Staehler, M., Schmerler, D., Junker, K., 2014.

AACR (San Diego) 901.

Indikation: Nierenzellkarzinom; Veranstaltung: AACR; Journal: -

MARC-2
2014

Effectiveness of 1st-line treatment options in mRCC – a German RCC-Registry evaluation.

Goebell, P.J., Müller, L., Lück, A., Overkamp, F., Vogt, M., Marschner, N., 2014.

J Clin Oncol, ASCO GU, San Francisco 32, (suppl.4; abstr 429). doi:10.1200/jco.2014.32.4_suppl.429

Indikation: Nierenzellkarzinom; Veranstaltung: GCS (ASCO); Journal: Journal of Clinical Oncology

TNK
2014

Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – Daten aus dem RCC-Register.

Goebell, P.-J., Müller, L., Hübner, A., Lück, A., Koska, M., Marschner, N., 2014.

oral presentation, DGU.

Indikation: Nierenzellkarzinom; Veranstaltung: DGU; Journal: -

TNK
2014

A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study.

Goebell, P., Münch, A., Müller, L., Hurtz, H.-J., Koska, M., Busies, S., Marschner, N., 2014.

Urol Oncol 32, 362–370. doi:10.1016/j.urolonc.2013.09.009

Indikation: Nierenzellkarzinom; Veranstaltung: -; Journal: Urologic Oncology

TNK
2014

Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – Daten aus dem RCC-Register.

Eder E, Müller L, Hübner A, Koska M, Marschner N, Goebell P-J, 2014.

Oral presentation at Gemeinsame Tagung BUV/OEGU. 2014;(FV17).

Indikation: Nierenzellkarzinom; Veranstaltung: Bayrische Urologenvereinigung; Journal: -

TNK
2014

SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) / sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Weikersthal, L.F. von, Goebell, P.J., de Santis, M. de, Lerchenmüller, C., Zimmermann, U., Bos, M.M.E.M., Freier, W., Schirrmacher-Memmel, S., Staehler, M.D., Pahernik, S., Los, M., Schenck, M., Flörcken, A., van Arkel, C.V., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., Michel, M.S., 2014.

Oncol Res Treat 37 (suppl 5)(V28), 5. doi:10.1159/000368945

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

RCC-SWITCH
2014

Patients with brain metastases from advanced or metastatic renal cell carcinoma – Data from the clinical RCC Registry.

Müller, L., Goebell, P., Reichert, D., Krieger, J., Jänicke, M., Harde, J., Koska, M., Marschner, N., 2014.

Oncol Res Treat 37 (suppl.5)(P287), 91. doi:10.1159/000368945

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2014

Interim analysis of a non-interventional study evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus (EVERPRO).

Bergmann, L., Goebell, P., Kloß, S., Schirrmacher-Memel, S., Warnack, W., Kube, U., Scheffler, M., Doehn, C., Marschner, N., Rosé, C., Herrmann, E., 2014.

Oncol Res Treat 37 (suppl.5)(P282), 89. doi:10.1159/000368945

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

EVERPRO
2014

Body-mass-index and survival of patients with metastastic renal cell carcinoma: Data from the German prospective RCC Registry.

Müller, L., Goebell, P.J., von Verschuer, U., Hurtz, H.-J., Franzem, M., Vogt, M., Marschner, N., 2013.

Onkologie 36 (suppl. 7)(V41), 10. doi:10.1159/000356365

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TNK
2013

Body-mass-index and survival of patients with metastastic renal cell carcinoma: Data from the German prospective RCC Registry.

Müller, L., Goebell, P., von Verschuer, U., Hurtz, H., Franzem, M., Vogt, M., Marschner, N., 2013.

J Clin Oncol 31 (suppl 6; abstr 454) doi:10.1200/jco.2013.31.6_suppl.454

Indikation: Nierenzellkarzinom; Veranstaltung: GCS (ASCO); Journal: Journal of Clinical Oncology

TNK
2013

Prediction of second-line therapy response in metastatic renal cell carcinoma patients by blood plasma marker proteins.

Hölters, S., Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Staehler, M., Schmerler, D., Junker, K., 2013.

Meeting of the EAU Section of Urological Research P17.

Indikation: Nierenzellkarzinom; Veranstaltung: ESUR (EAU); Journal: -

MARC-2
2013

Effectiveness of sequential treatment of advanced or metastatic renal cell carcinoma (mRCC). Outcome data from the clinical RCC Registry.

Goebell, P.J., Müller, L., Lück, A., Overkamp, F., Vogt, M., Marschner, N., 2013.

Onkologie 36 (suppl. 7)(V40), 8. doi:10.1159/000356365

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TNK
2013

The German mRCC Registry – aims and results after the first 1000 patients.

Goebell, P.J., Müller, L., Blumenstengel, K., Hübner, A., Lück, A., Vogt, M., Marschner, N., 2013.

Eur Urol Suppl 2013;12;e1106 DOI:10.1016/S1569-9056(13)61581-X

Indikation: Nierenzellkarzinom; Veranstaltung: EAU; Journal: -

TNK
2013

MARC-2: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy

Staehler, M, Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Schaller, F., Straßl, L., Junker, K., 2012.

J Cancer Res Clin Oncol (2012) 138(Suppl 1): 1. doi:10.1007/s00432-011-1144-4 (0327), 141–142.

Indikation: Nierenzellkarzinom; Veranstaltung: DKK; Journal: Journal of Cancer Research and Clinical Oncology

MARC-2
2012

MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

Staehler, MD, Bergmann, L., Grünwald, V., Huschke, T., Keilholz, U., Ohlmann, C., Stöckle, M., Weigang-Koehler, K., Hauswald, K., Schaller, F., Strassl, L., Junker, K., 2012.

J Clin Oncol 30(suppl 5; abstr 467). doi: 10.1200/jco.2012.30.5_suppl.467

Indikation: Nierenzellkarzinom; Veranstaltung: GCS (ASCO); Journal: Journal of Clinical Oncology

MARC-2
2012

Sequential systemic treatments of patients with metastatic renal cell carcinoma in German oncology and onco-urology outpatient centers. Data from the clinical RCC Registry.

Müller, L., Goebell, P., Harich, H., Vogt, M., Marschner, N., 2012.

Onkologie 35 (suppl 6)(V684), 203. doi:10.1159/000178474

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TNK
2012

How to further solidify data on systemic therapy in metastatic renal cell carcinoma (mRCC) in German mRCC registry on the treatment reality.

Goebell, P., Müller, L., Blumenstengel, K., Hübner, A., Lück, A., Koska, M., Marschner, N., 2012.

Eur Urol Suppl 2012;11,e79a DOI:10.1016/S1569-9056(12)60078-5

Indikation: Nierenzellkarzinom; Veranstaltung: EAU; Journal: -

TNK
2012

TNK
2011

Histology, metastases and palliative surgery in mRCC patients. Data from a clinical registry – RCC Registry.

Müller, L., Münch, A., Goebell, P., Hübner, A., Koska, M., Marschner, N., 2011.

Onkologie 34 (suppl 6)(P616), 182.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TNK
2011

Real-life treatment of patients with advanced or metastatic renal cell carcinoma in German oncology and urology outpatient centers (RCC-Registry).

Müller, L., Goebell, P.J., Blumenstengel, K., Lueck, A., Koska, M., Marschner, N., 2011.

J Clin Oncol 29 (suppl 7)(Abstract 367). doi:10.1200/jco.2011.29.7_suppl.367

Indikation: Nierenzellkarzinom; Veranstaltung: GCS (ASCO); Journal: Journal of Clinical Oncology

TNK
2011

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com